TP53 and acute myeloid leukemia: Notably, BAX expression (MV4-11: control vs 250 μM,P < 0.05; control vs 500 μM,P < 0.01; MOLM-13: control vs 250 μM,P < 0.01; control vs 500 μM, P<0.01) decreased, whereas BCL2 expression (MV4-11: control vs 250 μM,P < 0.05; control vs 500 μM,P < 0.05; MOLM-13: control vs 250 μM,P < 0.05; control vs 500 μM,P < 0.05) significantly increased in wild-type AML cells after ferric citrate treatment (Figure 3D,E), with no changes observed in mutant TP53 AML cells.